Loading…
Clinical-stage biotech developing obicetrapib, an oral CETP inhibitor to lower LDL cholesterol for cardiovascular disease.
Clinical-stage biotech developing obicetrapib, an oral CETP inhibitor to lower LDL cholesterol for cardiovascular disease.
Has no approved product yet, so it relies on money raised from investors and on a licensing deal with Menarini, which holds the right to sell obicetrapib in Europe once approved and owes milestone and royalty payments back. Late-stage trials, including one on heart-attack and stroke outcomes, are what the value rests on.
Moat: none (IP / patents). Pre-commercial; must differentiate after past CETP-inhibitor failures at other companies.
Headquarters: Naarden, Netherlands · Founded: 2019 · Employees: 100
Size NewAmsterdam Pharma (NAMS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.26B, the 1717th largest of 3,117 United States companies the cockpit tracks. Shares closed at $18.90 on 6 Nov 2026.
Performance Over six months the shares fell 51.2%, against -6.5% for the median peer and -1.1% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue fell 26.4% over the last twelve months (peer median +0.1%); the operating margin is -900.1% (peer median 9.7%).
Valuation It trades at 62.8× enterprise value to sales against a peer median of 3.4× (most expensive of 20).
Short interest Short interest is 11.8% of the free float (15 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $25.9M | $22.5M | $45.6M | $14.1M | $103M |
| Revenue growth | — | -51% | +223% | -86% | — |
| Gross profit | $25.7M | $22.3M | $45.5M | $14.0M | $103M |
| EBITDA | -$233M | -$225M | -$176M | -$181M | -$1.31M |
| Net income | -$205M | -$204M | -$242M | -$177M | -$22.6M |
| Free cash flow | -$151M | -$148M | -$159M | -$141M | $10.4M |
| Capital expenditure | $395,000 | $246,000 | $672,000 | $24,000 | $221,000 |
| Total debt | $76,000 | $202,000 | $448,000 | $60,000 | $126,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| NewAmsterdam Pharma NAMS | $2.26B | -51% | -26% | -900% | 62.8× | n/a |
| Novartis NOVN.SW | $298B | +15% | -4% | 30% | 6.3× | 1.7% |
| Amgen AMGN | $249B | +40% | +9% | 36% | 7.4× | 1.8% |
| Regeneron Pharmaceuticals REGN | $93.5B | +27% | +19% | 30% | 5.2× | -2.2% |
| Merck & MRK | $362B | +33% | +5% | 18% | 5.4× | 4.1% |
| AstraZeneca AZN.L | $291B | +1% | +5% | 23% | 5.1× | 14.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NAMS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.1% | +0.7% | 2nd lowest of 21 |
| 6-month return | -51.2% | -6.5% | lowest of 21 |
| Distance from 52-week high | -55.2% | -25.4% | lowest of 21 |
| Revenue growth (TTM) | -26.4% | +0.1% | 2nd lowest of 20 |
| Operating margin | -900.1% | 9.7% | lowest of 19 |
| EV / Sales | 62.8× | 3.4× | most expensive of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma NAMS | United States | $2.26B | -51% | -26% | -900% | 62.8× | n/a | n/a |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.26B | -35% | 0% | -47% | 34.7× | n/a | n/a |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.29B | -14% | +18% | n/a | 4.4× | 1.6% | +0.3% |
| InnoCare Pharma 9969.HK | Hong Kong | $2.31B | -13% | +146% | 35% | 3.4× | 0.8% | +341.1% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.31B | -7% | +4% | 10% | 1.5× | -2.2% | -5.8% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.32B | +18% | -7% | 15% | 1.8× | -9.1% | -1.5% |
| Perrigo PRGO | United States | $2.20B | +35% | -4% | 5% | 1.3× | 13.1% | +0.8% |
| Biohaven BHVN | United States | $2.19B | +47% | n/a | n/a | n/a | n/a | n/a |
| Haw Par H02.SI | Singapore | $2.18B | -27% | -13% | 30% | 8.9× | 3.7% | +15.7% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.15B | -3% | +9% | 14% | 3.4× | 6.1% | +6.4% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $2.13B | -27% | +5% | -18% | 30.2× | n/a | n/a |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $2.12B | -41% | -18% | 9% | 15.5× | 37.9% | +0.9% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.12B | +17% | -1% | 14% | 2.5× | 2.4% | +15.7% |
| Dermapharm DMP.DE | Germany | $2.11B | -25% | 0% | 22% | 2.4× | -3.8% | +8.0% |
| Zymeworks ZYME | United States | $2.10B | +24% | -70% | -419% | 56.6× | n/a | n/a |
| Harbin Pharmaceutical 600664.SS | China | $2.10B | +55% | +2% | 5% | 0.9× | -2.9% | +8.2% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.48B | -6% | 0% | -73% | 17.5× | n/a | n/a |
| Jinyu Bio-Technology 600201.SS | China | $2.04B | -15% | +22% | 10% | 7.7× | 24.4% | -2.4% |
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 3.6× | -0.2% | +2.9% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.02B | +7% | +5% | 22% | 3.2× | -4.8% | +10.6% |
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 2.2× | 11.9% | +5.0% |